FDA accepts Gilead's Quad HIV regimen NDA for review

Download PDF Copy

Editorial Checklist

Reviewed

Gilead Sciences, Inc.Dec 26 2011

NewsGuard 100/100 Score

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for the Quad, a complete single-tablet HIV regimen containing elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate.

Gilead submitted the Quad NDA on October 27, 2011. The FDA has set a target review date for the Quad under the Prescription Drug User Fee Act (PDUFA) of August 27, 2012.

Source:

Gilead Sciences, Inc.

Posted in: Disease/Infection News | Pharmaceutical News

Tags: Antiretroviral, Emtricitabine, Food, HIV, HIV/AIDS, HIV-1, New Drug Application, Prescription Drug, Tenofovir, Tobacco, Truvada, Virus

Comments (0)

Download PDF Copy

Suggested Reading

Study shows safety of kidney transplants among those with HIV infections

Study shows safety of kidney transplants among those with HIV infections

Exclusion of indigenous voices hinders HIV progress in Latin America

Exclusion of indigenous voices hinders HIV progress in Latin America

Affordability and supply remain critical to the success of long-lasting HIV drug

Affordability and supply remain critical to the success of long-lasting HIV drug

New two-dose HIV vaccine strategy shows promise for stronger immune response

New two-dose HIV vaccine strategy shows promise for stronger immune response

Study uncovers key mechanism behind HIV latency

Study uncovers key mechanism behind HIV latency

Iron supplements may boost brain development in children with HIV

Iron supplements may boost brain development in children with HIV

Sweden becomes first country to meet global HIV targets

Sweden becomes first country to meet global HIV targets

Historical redlining continues to affect HIV treatment in affected communities

Historical redlining continues to affect HIV treatment in affected communities

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Sweden exceeds UNAIDS HIV goals but faces new challenges